H.C. Wainwright lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $56 from $61 and keeps a Buy rating on the shares. The company’s newly established European partner Avanzanite announced the signing of a commercial and distribution agreement between the companies for Pyrukynd in Europe, Switzerland, and the United Kingdom, the analyst tells investors in a research note. The firm says that while specific details regarding the deal’s capital structure were not disclosed, the companies noted that the partnership is a revenue share agreement, similar to Agios’ gulf coast region partnership with Newbridge, and will include current as well as future indications for Pyrukynd. H.C. Wainwright is now not modeling any milestone or royalty payments based on the agreement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios to highlight PK activation portfolio with data in blood disorders at EHA
- Hold Rating for Agios Pharma Amid Regulatory Milestones and Financial Uncertainty
- Agios Pharmaceuticals price target lowered to $71 from $74 at Scotiabank
- Agios Pharmaceuticals Reports Q1 2025 Progress and Outlook
- Agios Pharmaceuticals’ Earnings Call: Optimism Amid Challenges